USA flag logo/image

An Official Website of the United States Government

Development of Serum Based Biomarker for the Detection of Cancer

Award Information

Agency:
Department of Defense 		Branch:
Office of the Secretary of Defense 		Award ID:
61227 		Program Year/Program:
2002 / SBIR
Agency Tracking Number:
O2-0057 		Solicitation Year:
N/A 		Solicitation Topic Code:
N/A 		Solicitation Number:
N/A
Small Business Information
Chromotrax, Inc.
Chromotrax, Inc. 2000 N 14Th St, Ste 530 Arlington, VA 22201 0250
View profile »
Woman-Owned: Yes
Minority-Owned: Yes
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2002
Title: Development of Serum Based Biomarker for the Detection of Cancer
Agency / Branch: DOD / OSD
Contract: DAMD17-02-C-0008
Award Amount: $749,999.00
 

Abstract:

"We propose an innovative technique for ultra rapid, sensitive detection ofcancer specific chromosome rearrangements in solution to facilitate bulkquantification of aberrant chromosomes for early detection of metastatictumor cells. (I) We will apply DNA hybridization in suspension to humanbreast cancer cell lines by combining two separate, novel techniques 1)hybridizing chromosomes in suspension; 2) using repeat sequence deplete DNAprobes in combination with a flow cytometric method of analysis and magneticsorting, in order to sensitively, precisely and rapidly quantifycancer-related chromosome translocations and rearrangements. Chromosomeaberrations will be detected using reversible DNA-hybridization probes thatuniquely bind to DNA normally present in a specific subset of the genome. Asecond set of reversible DNA hybridization probes will be used to uniquelyhybridize with a corresponding second subset of the genome. Any (aberrant)chromosomes containing both subsets will be rapidly and efficiently isolatedand quantified. (II) We will determine the translocation detectionsensitivity (has a potential sensitivity of 1x1,000,000) using serialdilutions of a human breast cancer cell line with known translocation withthe lymphoblast cell line AG122. We expect our technique will havesensitivity similar to PCR and far higher than FISH, with specificity betterthan PCR."

Principal Investigator:

Joe Lucas
Principal Investigator
9258281095
lcjoe@aol.com

Business Contact:

Loretta Chi
President
7035583400
chi@altechnologies.com
Small Business Information at Submission:

A.L.Tech Biomedical, Inc.
9700 Great Seneca Highway #194 Rockville, MD 20850

EIN/Tax ID: 542021057
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No